无糖尿病患者中二甲双胍使用与年龄相关性黄斑变性的关联
基于2006至2017年美国全国保险索赔数据库的病例对照研究,纳入无糖尿病诊断的231142例任何AMD患者与232879例匹配对照,发现二甲双胍暴露与任何AMD(AOR 0.83;95%CI 0.74-0.87)及干性AMD(AOR 0.85;95%CI 0.79-0.92)发生几率降低相关,且关联不呈剂量依赖性。
要点
- 无糖尿病患者中,二甲双胍暴露与任何AMD发生几率降低相关(AOR 0.83;95%CI 0.74-0.87)。
- 二甲双胍暴露与干性AMD发生几率降低相关(AOR 0.85;95%CI 0.79-0.92)。
- 任何AMD与干性AMD的调整比值比在各剂量四分位组间无差异,趋势检验P=.51与P=.66。
核心结论
- 在无糖尿病诊断的人群中,二甲双胍使用与AMD发生几率降低相关。
- 该关联似乎不呈剂量依赖性。
- 作者认为这些发现为进一步在前瞻性临床试验中研究二甲双胍对AMD的保护作用提供了动力。
研究设计与样本
- AMD病例与无AMD对照按年份、年龄、贫血、高血压、地区和Charlson共病指数评分1:1匹配,随后筛选无糖尿病诊断的病例与匹配对照。
- 共纳入231142例任何AMD患者(平均[SD]年龄75.1[10.4]岁;女性140172例[60.6%])和232879例匹配对照(平均[SD]年龄74.9[10.5]岁;女性133670例[57.4%])。
- 亚组分析纳入144147例干性AMD病例并与144530例对照匹配。
- 数据分析于2023年3月至9月进行。
主要发现
- 任何AMD病例中2268例(1.0%)和对照中3087例(1.3%)在索引日期前2年内有二甲双胍暴露。
- 经多变量条件logistic回归调整后,任何二甲双胍暴露与任何AMD发生几率降低相关(AOR 0.83;95%CI 0.74-0.87),在1至270、271至600和601至1080 g/2 y剂量四分位组中显著。
- 任何二甲双胍暴露与干性AMD发生几率降低相关(AOR 0.85;95%CI 0.79-0.92),在1至270和271至600 g/2 y剂量四分位组中显著。
- 任何AMD与干性AMD的调整比值比在各剂量四分位组间无差异;Cochran-Armitage趋势检验双侧P值分别为.51和.66。
关键数值与推荐
- 二甲双胍暴露定义为索引日期前2年内累积剂量,分为1-270、271-600、601-1080和>1080 g/2 y四分位组。
- 任何AMD:AOR 0.83(95%CI 0.74-0.87)。
- 干性AMD:AOR 0.85(95%CI 0.79-0.92)。
- 趋势检验:任何AMD样本P=.51,干性AMD样本P=.66(双侧)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Metformin use may protect against the development of age-related macular degeneration (AMD) based on results from observational studies. However, its potential effectiveness among patients without diabetes remains unclear. OBJECTIVE: To assess the association between metformin use and the development of AMD in patients without diabetes. DESIGN, SETTING, AND PARTICIPANTS: This case-control study used data from 2006 to 2017 in the Merative MarketScan Research Database, a nationwide insurance claims database that includes between 27 and 57 million patients in the US with primary or Medicare supplemental health insurance. Cases with AMD and controls without AMD aged 55 years or older were matched 1:1 by year, age, anemia, hypertension, region, and Charlson Comorbidity Index score. Then, cases and matched controls without a diagnosis of diabetes were selected. In subgroup analyses, cases with dry AMD and their matched controls were identified to explore the association between metformin use and AMD staging in patients without diabetes. Data were analyzed between March and September 2023. EXPOSURES: Exposure to metformin in the 2 years prior to the index date (ie, date of AMD diagnosis in cases and date of a randomly selected eye examination for controls) was assessed from the claims database and categorized into quartiles based on cumulative dose (1-270, 271-600, 601-1080, and >1080 g/2 y). Exposure to other antidiabetic medications was also noted. MAIN OUTCOMES AND MEASURES: Odds of new-onset AMD development as assessed by multivariable conditional logistic regression after adjusting for known risk factors for AMD, including female sex, hyperlipidemia, smoking, and exposures to other antidiabetic medications. Asymptotic Cochran-Armitage tests for trend were also performed. RESULTS: We identified 231 142 patients with any AMD (mean [SD] age, 75.1 [10.4] years; 140 172 females [60.6%]) and 232 879 matched controls without AMD (mean [SD] age, 74.9 [10.5] years; 133 670 females [57.4%]), none of whom had a diagnosis of diabetes. The sample included 144 147 cases with dry AMD that were matched to 144 530 controls. In all, 2268 (1.0%) cases and 3087 controls (1.3%) were exposed to metformin in the 2 years before their index visit. After data adjustment, exposure to any metformin was associated with reduced odds of any AMD development (adjusted odds ratio [AOR], 0.83; 95% CI, 0.74-0.87), specifically in the dosing quartiles of 1 to 270, 271 to 600, and 601 to 1080 g/2 y. Any metformin use was also associated with a reduced odds of developing dry AMD (AOR, 0.85; 95% CI, 0.79-0.92), specifically in the dosing quartiles of 1 to 270 and 271 to 600 g/2 y. Adjusted odds ratios for any AMD and dry AMD development did not differ across the dosing quartiles. Asymptotic Cochran-Armitage tests for trend revealed 2-sided P = .51 and P = .66 for the any and dry AMD samples, respectively. CONCLUSIONS AND RELEVANCE: In this case-control study of a population without a diagnosis of diabetes, metformin use was associated with reduced odds of developing AMD. This association does not appear to be dose dependent. These findings provide further impetus to study metformin's usefulness in protecting against AMD in prospective clinical trials.
引用
- Aggarwal S, Moir J, Hyman MJ, et al. Metformin Use and Age-Related Macular Degeneration in Patients Without Diabetes. JAMA Ophthalmol. 2024. PMID: 38019527. doi:10.1001/jamaophthalmol.2023.5478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。